Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 29 of 29 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/24/18
End: 07/16/21
Due: 07/16/22
Phase: N/A
Priority: Normal
Start: 08/01/17
End: 08/17/20
Due: 08/17/21
Phase: N/A
Priority: Normal
Start: 09/22/20
End: 12/08/20
Due: 12/08/21
Phase: N/A
Priority: Normal
Start: 10/10/17
End: 12/17/19
Due: 12/17/20
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma | NCT03428217 | Calithera Biosciences, Inc | user2@example.com | None | 2018-04-24 | 2021-07-16 | 2022-07-16 | - | - | 2025-07-14 |
| A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) | NCT03238651 | Calithera Biosciences, Inc | user2@example.com | None | 2017-08-01 | 2020-08-17 | 2021-08-17 | - | - | 2025-07-14 |
| Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects | NCT04540965 | Calithera Biosciences, Inc | user2@example.com | None | 2020-09-22 | 2020-12-08 | 2021-12-08 | - | - | 2025-07-14 |
| TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | NCT03123393 | Calithera Biosciences, Inc | user2@example.com | None | 2017-10-10 | 2019-12-17 | 2020-12-17 | - | - | 2025-07-14 |